Compound News and Research

RSS

Targeted therapies that attack stem cell-like cancer cells can prevent spread of prostate cancer

A successful interdisciplinary project is underway between two research groups, in which senior researcher Rebecka Hellsten and Professor Anders Bjartell at the Faculty of Medicine's division for Urological Cancer Research, Sk-ne University Hospital in Malm-, and Professor Olov Sterner and Assistant Professor Martin Johansson at the Lund University division of Organic Chemistry recently published their latest research findings in the scientific online journal PLoS ONE.

12 Aug 2011

Galectin second quarter net loss increases to $3.9 million

Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the second quarter and first six months, ended June 30, 2011.

12 Aug 2011

Tanning beds may spur addictive neurological reward and reinforcement trigger

People who frequently use tanning beds may be spurred by an addictive neurological reward-and-reinforcement trigger, researchers at UT Southwestern Medical Center have found in a pilot study.

12 Aug 2011

Researchers to develop new prostate cancer therapy

Prostate cancer that has become resistant to hormone treatment and that does not respond to radiation or chemotherapy requires new methods of treatment. By attacking stem cell-like cells in prostate cancer, researchers at Lund University are working on a project to develop a new treatment option.

12 Aug 2011

FDA assigns PDUFA action date for review of Affymax peginesatide NDA

Affymax, Inc. today announced that the U.S. Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action date of March 27, 2012 for the review of the investigational agent peginesatide New Drug Application.

12 Aug 2011

BCG vaccine can help immune system recognise cancer cells as 'foreign'

Scientists have found a potential new mechanism to stimulate the body's own ability to fight cancer using Baculillus Calmette-Guerin (BCG) - the germ commonly used to inoculate against tuberculosis.

11 Aug 2011

Pharma IQ to launch Compound Management and Integrity Online event

Pharma IQ is pioneering new compound management discussion platform with launch of the first ever compound management event - Compound Management and Integrity Online event, which will take an innovative form of 11 online session over the course of 5 weeks, beginning 31st of October 2011.

11 Aug 2011

Gastroenterology journal publishes results of Lexicon LX1031 Phase 2 trial in IBS

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that results from the Phase 2 clinical trial of LX1031 in patients with non-constipating irritable bowel syndrome (IBS) were published earlier this week in the August 2011 edition of the journal Gastroenterology.

11 Aug 2011

Global endoscopy equipment market to reach $33.7 billion by 2016: New report

By 2016 it is believed that the global endoscopy equipment market will be worth in excess of $33.7 billion, growing at a CAGR of 6.4% over the reporting period, according to a new report available on companiesandmarkets.com.

10 Aug 2011

New report: U.S. antiseptics and disinfectants market to reach $2.9B by 2016

In 2009, the disinfectant and antiseptic market was worth around $3.4 billion, but by 2010 had grown over 12%, to reach a value of $3.8 billion, according to a new report available from companiesandmarkets.com.

9 Aug 2011

Common culinary spice derivative could treat tendinitis

A derivative of a common culinary spice found in Indian curries could offer a new treatment hope for sufferers of the painful condition tendinitis, an international team of researchers has shown.

9 Aug 2011

Pfizer, UC San Diego sign research agreement to drive innovation in drug discovery

In an innovative collaboration designed to speed the process of drug discovery, Pfizer, Inc. and the University of California, San Diego Health Sciences announced today that UC San Diego has joined the ranks of other top-tier life science research institutions across the country as part of Pfizer's Centers for Therapeutic Innovation.

9 Aug 2011

EPO issues European patent for Rexahn's neurotherapeutic compositions

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office (EPO) has granted European patent No. EP1212055 entitled "Neurotherapeutic compositions comprising a beta-lactam compound."

9 Aug 2011

Genentech, Array BioPharma sign oncology agreement for ChK-1 development program

Array BioPharma today announced an oncology agreement with Genentech, a member of the Roche Group, for the development of each company's small-molecule Checkpoint kinase 1 (ChK-1) program.

9 Aug 2011

Simcyp extends application in areas of PD modelling and drug distribution within CNS

Simcyp Limited is pleased to announce significant additions to its flagship simulator in line with priorities established by the Simcyp Consortium of global pharmaceutical companies.

6 Aug 2011

Idera second quarter net loss increases to $6.3 million

Idera Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-Like receptors (TLRs).

5 Aug 2011

Metallofullerene platform holds promise for treatment of brain tumors

A single compound with dual function - the ability to deliver a diagnostic and therapeutic agent - may one day be used to enhance the diagnosis, imaging and treatment of brain tumors, according to findings from Virginia Commonwealth University and Virginia Tech.

5 Aug 2011

Scientists identify small molecule inhibitors of cellular uptake

Scientists from Freie Universität Berlin and the NeuroCure Cluster of Excellence led by biochemist Volker Haucke in collaboration with colleagues from Australia and the Leibniz Institute for Molecular Pharmacology in Berlin have developed small molecules that inhibit the internalization of important signaling molecules but also of pathogenic organisms such as the immunodeficiency virus and bacteria into cells.

5 Aug 2011

New polymer effectively captures nicotine molecules and analogues

Newly synthesized polymer, fitted with molecular pincers of carefully tailored structure, effectively captures nicotine molecules and its analogues.

5 Aug 2011

YM BioSciences reports preclinical results of CYT387 in multiple myeloma

YM BioSciences Inc., today reported preclinical results for its JAK1/JAK2 inhibitor CYT387 in multiple myeloma (MM), published in the advance online edition of Leukemia on July 26, 2011.

5 Aug 2011